149 related articles for article (PubMed ID: 29170809)
41. [Cutaneous infiltratiton by chronic myelononocytic leukemia: presentation of three cases].
Prada Garcia C; Sanchez Sambucety P; Rodriguez Prieto MÁ
Dermatol Online J; 2013 Nov; 19(11):20408. PubMed ID: 24314783
[TBL] [Abstract][Full Text] [Related]
42. Nitric oxide and prostacyclin in acute interstitial pneumonia.
Ho TB; Rhodes A
J R Soc Med; 2002 Jan; 95(1):35-7. PubMed ID: 11773351
[No Abstract] [Full Text] [Related]
43. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).
Wijermans PW; Rüter B; Baer MR; Slack JL; Saba HI; Lübbert M
Leuk Res; 2008 Apr; 32(4):587-91. PubMed ID: 17881052
[TBL] [Abstract][Full Text] [Related]
44. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study.
Mekinian A; Grignano E; Braun T; Decaux O; Liozon E; Costedoat-Chalumeau N; Kahn JE; Hamidou M; Park S; Puéchal X; Toussirot E; Falgarone G; Launay D; Morel N; Trouiller S; Mathian A; Gombert B; Schoindre Y; Lioger B; De Wazieres B; Amoura Z; Buchdaul AL; Georgin-Lavialle S; Dion J; Madaule S; Raffray L; Cathebras P; Piette JC; Rose C; Ziza JM; Lortholary O; Montestruc F; Omouri M; Denis G; Rossignol J; Nimubona S; Adès L; Gardin C; Fenaux P; Fain O
Rheumatology (Oxford); 2016 Feb; 55(2):291-300. PubMed ID: 26350487
[TBL] [Abstract][Full Text] [Related]
45. Fibrotic Lung Toxicity Induced by Hydroxycarbamide.
Bargagli E; Palazzi M; Perri F; Torricelli E; Rosi E; Bindi A; Pistolesi M; Voltolini L
In Vivo; 2017; 31(6):1221-1223. PubMed ID: 29102950
[TBL] [Abstract][Full Text] [Related]
46. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.
Oki Y; Jelinek J; Shen L; Kantarjian HM; Issa JP
Blood; 2008 Feb; 111(4):2382-4. PubMed ID: 18055864
[TBL] [Abstract][Full Text] [Related]
47. A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia.
Tantravahi SK; Szankasi P; Khorashad JS; Dao KH; Kovacsovics T; Kelley TW; Deininger MW
Leuk Lymphoma; 2016 Oct; 57(10):2441-4. PubMed ID: 26752680
[No Abstract] [Full Text] [Related]
48. Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.
Voso MT; Breccia M; Lunghi M; Poloni A; Niscola P; Finelli C; Bari A; Musto P; Zambello R; Fianchi L; Alimena G; Leone G
Eur J Haematol; 2013 Apr; 90(4):345-8. PubMed ID: 23336938
[TBL] [Abstract][Full Text] [Related]
49. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.
Meldi K; Qin T; Buchi F; Droin N; Sotzen J; Micol JB; Selimoglu-Buet D; Masala E; Allione B; Gioia D; Poloni A; Lunghi M; Solary E; Abdel-Wahab O; Santini V; Figueroa ME
J Clin Invest; 2015 May; 125(5):1857-72. PubMed ID: 25822018
[TBL] [Abstract][Full Text] [Related]
50. Pulmonary hypertension in a child with juvenile myelomonocytic leukemia secondary to pulmonary leukemic cell infiltration.
Alioglu B; Demirhan B; Ozyurek E; Varan B; Erbay A; Ozbek N
Pediatr Hematol Oncol; 2006 Dec; 23(8):667-75. PubMed ID: 17065143
[TBL] [Abstract][Full Text] [Related]
51. Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia.
Huemer F; Weiss L; Faber V; Neureiter D; Egle A; Geissler K; Voskova D; Zebisch A; Burgstaller S; Pichler A; Stauder R; Sperr W; Lang A; Pfeilstöcker M; Machherndl-Spandl S; Stampfl M; Greil R; Pleyer L
Wien Klin Wochenschr; 2018 Feb; 130(3-4):115-125. PubMed ID: 29383443
[TBL] [Abstract][Full Text] [Related]
52. Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment.
Yi JH; Huh J; Kim HJ; Kim SH; Kim SH; Kim KH; Do YR; Mun YC; Kim H; Kim MK; Kim HJ; Kim T; Kim DD
Ann Hematol; 2013 Apr; 92(4):459-69. PubMed ID: 23262795
[TBL] [Abstract][Full Text] [Related]
53. Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone.
Almeida AM; Pierdomenico F
Leuk Res; 2012 Sep; 36(9):e211-3. PubMed ID: 22622173
[No Abstract] [Full Text] [Related]
54. Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7.
Furlan I; Batz C; Flotho C; Mohr B; Lübbert M; Suttorp M; Niemeyer CM
Blood; 2009 Mar; 113(12):2867-8. PubMed ID: 19299654
[No Abstract] [Full Text] [Related]
55. Octasomy 21 in a patient with secondary AML after CMML: the role of acquired NRAS mutations in triggering aneuploidy.
Thomay K; Behrens YL; Lentes J; Wittner N; Wittig V; Rothe D; Steinemann D; Schlegelberger B; Göhring G
Leuk Lymphoma; 2018 Oct; 59(10):2478-2481. PubMed ID: 29384408
[No Abstract] [Full Text] [Related]
56. Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.
Laille E; Shi T; Garcia-Manero G; Cogle CR; Gore SD; Hetzer J; Kumar K; Skikne B; MacBeth KJ
PLoS One; 2015; 10(8):e0135520. PubMed ID: 26296092
[TBL] [Abstract][Full Text] [Related]
57. Azacitidine-Induced Interstitial Pneumonitis.
Verriere B; Ferreira V; Denis E; Zahreddine K; Deletie E; Quinsat D; Re D
Am J Ther; 2016; 23(5):e1205-8. PubMed ID: 26371947
[TBL] [Abstract][Full Text] [Related]
58. Modifying disease in CMML: who responds to Azacitidine?
Almeida A
Leuk Res; 2013 Jun; 37(6):603-4. PubMed ID: 23453287
[No Abstract] [Full Text] [Related]
59. Interstitial pneumonitis after treatment with pemetrexed: a rare event?
Hochstrasser A; Benz G; Joerger M; Templeton A; Brutsche M; Früh M
Chemotherapy; 2012; 58(1):84-8. PubMed ID: 22377772
[TBL] [Abstract][Full Text] [Related]
60. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.
Parikh SA; Tefferi A
Am J Hematol; 2013 Nov; 88(11):967-74. PubMed ID: 23963888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
